GlassScriptPhysician profile
Daniel Dume-Charles
NPI 1578588182
$3,115.22
in general payments reported to CMS, 2019-2025
18 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $187 · 2021: $130 · 2022: $354 · 2023: $353 · 2024: $879 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,330.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $829.23 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $566.60 | 2020-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $530.36 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $208.06 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.80 | 2019-2023 | Tradjenta |
| Kowa Pharmaceuticals America, INC. | $160.52 | 2024-2025 | Zoryve |
| Astellas Pharma US INC | $129.26 | 2023-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $118.71 | 2025 | |
| Gilead Sciences, INC. | $118.71 | 2025 | Livdelzi |
| Ardelyx, INC. | $54.59 | 2024 | Ibsrela |
| Exact Sciences Corporation | $42.12 | 2024 | Cologuard Collection Kit |
| Global Blood Therapeutics, INC. | $39.25 | 2020 | |
| Amgen INC. | $37.53 | 2024 | Repatha, Otezla |
| Abbott Laboratories | $24.89 | 2023 | Freestyle Libre 2 |
| Corcept Therapeutics | $24.25 | 2025 | Korlym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $23.24 | 2021 | |
| Horizon Therapeutics Plc | $22.99 | 2022 | |
| Abbvie INC. | $21.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Dume-Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.